Аннотация:
Non-small cell lung carcinoma (NSCLC) is the major cause of cancer-associated mortality. Identification of rearrangements in anaplastic lymphoma kinase (ALK) gene is an effective instrument for more effective targeted therapy of NSCLC using ALK inhibitors dramatically raising progression-free survival in the ALK-mutated group of patients. However, the tumors frequently develop resistance to ALK inhibitors. We describe here a case of 48 y.o. male patient with ALK-positive NSCLC who was clinically managed for 6.5 years from the diagnosis. The tumor was surgically resected, but 8 months later multiple brain metastases were discovered. The patient started receiving platinum-based chemotherapy and then was enrolled in a clinical trial of second-generation ALK inhibitor ceritinib, which resulted in a 21 months stabilization. Following disease relapse, the patient was successfully managed for 33 months with different lines of chemo- and local ablative therapies. Chemotherapy regimens, includi
Poddubskaya E. V. Elena Vladimirovna 1965-
Bondarenko A.
Boroda A. M. Aleksandr Mojseevich 1977-
Zotova E. O. Ekaterina Olegovna 1994-
Glusker A. A. Aleksandr Aronovich 1965-
Sletina S.
Makovskaia L.
Kopy'lov F. Yu. Filipp Yuryevich 1976-
Sekacheva M. I. Marina Igorevna 1976-
Moiseev A. A. Aleksej Andreevich 1978-
Baranova M.
Поддубская Е. В. Елена Владимировна 1965-
Бондаренко А.
Борода А. М. Александр Мойсеевич 1977-
Зотова Е. О. Екатерина Олеговна 1994-
Глускер А. А. Александр Аронович 1965-
Слетина С.
Маковскаиа Л.
Копылов Ф. Ю. Филипп Юрьевич 1976-
Секачева М. И. Марина Игоревна 1976-
Моисеев А. А. Алексей Андреевич 1978-
Баранова М.
Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK...
Текст визуальный непосредственный
Frontiers in Oncology
Vol.9 Num.1026
2019
Статья
ALK gene expression NSCLC personalized oncology transcriptomics
anaplastic lymphoma kinase anaplastic lymphoma kinase inhibitor bevacizumab ceritinib cisplatin crizotinib dexamethasone docetaxel pembrolizumab pemetrexed platinum topotecan vinorelbine tartrate add on therapy adjuvant therapy adult Article brain edema brain metastasis cancer recurrence case report clinical article clinical decision support system computer assisted tomography disease exacerbation drug dose reduction fluorescence in situ hybridization gene expression gene mutation gene rearrangement gene translocation headache human human tissue immunohistochemistry lung cancer lung metastasis male middle aged molecularly targeted therapy multiple cycle treatment non small cell lung cancer nuclear magnetic resonance imaging personalized medicine progression free survival quality of life stereotactic radiosurgery transcriptomics tumor volume whole brain radiotherapy
Non-small cell lung carcinoma (NSCLC) is the major cause of cancer-associated mortality. Identification of rearrangements in anaplastic lymphoma kinase (ALK) gene is an effective instrument for more effective targeted therapy of NSCLC using ALK inhibitors dramatically raising progression-free survival in the ALK-mutated group of patients. However, the tumors frequently develop resistance to ALK inhibitors. We describe here a case of 48 y.o. male patient with ALK-positive NSCLC who was clinically managed for 6.5 years from the diagnosis. The tumor was surgically resected, but 8 months later multiple brain metastases were discovered. The patient started receiving platinum-based chemotherapy and then was enrolled in a clinical trial of second-generation ALK inhibitor ceritinib, which resulted in a 21 months stabilization. Following disease relapse, the patient was successfully managed for 33 months with different lines of chemo- and local ablative therapies. Chemotherapy regimens, includi